Hovione completes pilot-scale blister manufacturing for its 'green' DPI

The device's blister is designed to provide flexibility to pharmaceutical partners delivering a wide range of inhaled drugs for both acute and chronic respiratory treatments.
Hovione Technology has completed pilot-scale blister manufacturing and filling for its new reusable blister-based dry powder inhaler, the Papillon DPI. Papillon targets global industry-leading inhaler affordability and environmental sustainability.
“This is an important milestone allowing Hovione Technology to deliver Papillion inhalers together with blister samples to its pharmaceutical partners with their new inhalable powder formulations in quantities suitable for initial development purposes,” said Peter Villax, Hovione Technology’s CEO.
Papillon’s blister is designed to provide flexibility to pharmaceutical partners delivering a wide range of inhaled drugs for both acute and chronic respiratory treatments. Its large cavity size enables filling doses of up to 50 mg and is compatible both with carrier-based and carrier-free powder formulations.
“We are excited to be working with Harro Höfliger, who are experts in powder filling technologies and industrial filling machines to establish a pilot-scale blister manufacturing solution for our Papillon DPI. We will continue to work with this partner to develop a manufacturing solution that can be smoothly integrated into standard, industrial-scale blister filling machines capable of high-volume commercial manufacturing for pharmaceutical partners”, said João Ventura Fernandes, Hovione Technology’s Director of Technology Development and Licensing.
The company's Papillon DPI is an innovative, single-dose reusable blister-based DPI of simple use. Manufactured from a single plastic part, Papillon unlocks a cost of goods per dose competitive to that of multi-dose inhalers at a fraction of the development cost and risk.

Related News
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease. -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance